Company / Return on Equity (ROE)
BIOCRYST PHARMACEUTICALS INC Return on Equity (ROE) History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-284.7%
FY2019
5-year range
-
FY2016-FY2019
Trend
-38.4%
vs FY2018
Sector context
#187 of 190
Health Care
What the data says
BIOCRYST PHARMACEUTICALS INC reports negative total equity of -284.7% in FY2019. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-284.7% in FY2019 with a 3-year CAGR of +3209.9%.
Declined from -78.5% to -284.7% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +3209.9pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 190This company -284.7% Sector average -50.4%
▼
-464.5% below sector average
Key checks
Key Insights
- In FY2019, return on equity (roe) decreased 38.4% year-over-year.
- Currently 234.3pp below the Health Care sector average.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | -284.7% | -38.4% |
| FY2018 | -205.7% | -161.9% |
| FY2017 | -78.5% | +97.8% |
| FY2016 | -3494.6% | -3776.8% |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026